Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Information

Summary of results of operations by segment

(In thousands)			Contract		Corporate		Total
Three Months Ended September 30, 2022	Therapeutics		Research		and Other		Company
Total revenue	$	17,928	$	4,299	$	(3,209)	$	19,018
Cost of revenue		—		3,925		(3,002)		923
Research and development expense		23,863		—		(207)		23,656
General and administrative expense		—		875		4,938		5,813
Licensing expense		7,300		—		—		7,300
Revaluation of contingent consideration		2,200		—		—		2,200
Loss from operations	$	(15,435)	$	(501)	$	(4,938)	$	(20,874)
(In thousands)			Contract		Corporate		Total
Three Months Ended September 30, 2021	Therapeutics		Research		and Other		Company
Total revenue	$	244	$	3,335	$	(1,920)	$	1,659
Cost of revenue		—		2,912		(1,813)		1,099
Research and development expense		14,083		—		(107)		13,976
General and administrative expense		—		837		5,142		5,979
Revaluation of contingent consideration		900		—		—		900
Loss from operations	$	(14,739)	$	(414)	$	(5,142)	$	(20,295)
(In thousands)			Contract		Corporate		Total
Nine Months Ended September 30, 2022	Therapeutics		Research		and Other		Company
Total revenue	$	18,469	$	12,795	$	(9,265)	$	21,999
Cost of revenue		—		11,823		(8,677)		3,146
Research and development expense		57,329		—		(588)		56,741
General and administrative expense		—		2,570		15,417		17,987
Licensing expense		7,300		—		—		7,300
Revaluation of contingent consideration		(2,400)		—		—		(2,400)
Loss from operations	$	(43,760)	$	(1,598)	$	(15,417)	$	(60,775)
(In thousands)			Contract		Corporate		Total
Nine Months Ended September 30, 2021	Therapeutics		Research		and Other		Company
Total revenue	$	704	$	10,016	$	(5,460)	$	5,260
Cost of revenue		—		8,705		(5,141)		3,564
Research and development expense		30,030		—		(319)		29,711
General and administrative expense		—		2,344		14,332		16,676
Revaluation of contingent consideration		22,139		—		—		22,139
Loss from operations	$	(51,465)	$	(1,033)	$	(14,332)	$	(66,830)